108 related articles for article (PubMed ID: 35366537)
1. Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.
Davern M; Donlon NE; O' Connell F; Sheppard AD; Hayes C; King R; Temperley H; Butler C; Bhardwaj A; Moore J; Bracken-Clarke D; Donohoe C; Ravi N; Reynolds JV; Maher SG; Conroy MJ; Lysaght J
Transl Oncol; 2022 Jun; 20():101406. PubMed ID: 35366537
[TBL] [Abstract][Full Text] [Related]
2. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
3. Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; Habash M; Sheppard AD; MacLean M; Dunne MR; Moore J; Temperley H; Conroy MJ; Butler C; Bhardwaj A; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
Cancer Immunol Immunother; 2023 Jan; 72(1):55-71. PubMed ID: 35708739
[TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.
Davern M; O' Brien RM; McGrath J; Donlon NE; Melo AM; Buckley CE; Sheppard AD; Reynolds JV; Lynam-Lennon N; Maher SG; Lysaght J
Sci Rep; 2022 Feb; 12(1):3259. PubMed ID: 35228614
[TBL] [Abstract][Full Text] [Related]
5. Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.
Davern M; Bracken-Clarke D; Donlon NE; Sheppard AD; Connell FO; Heeran AB; Majcher K; Conroy MJ; Mylod E; Butler C; Donohoe C; Donnell DO; Lowery M; Bhardwaj A; Ravi N; Melo AA; Sullivan JO; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6583-6599. PubMed ID: 36790524
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells.
Davern M; Donlon NE; Sheppard A; Connell FO; Hayes C; Bhardwaj A; Foley E; Toole DO; Lynam-Lennon N; Ravi N; Reynolds JV; Maher SG; Lysaght J
Transl Oncol; 2021 Jun; 14(6):101062. PubMed ID: 33765543
[TBL] [Abstract][Full Text] [Related]
7. FLOT and CROSS chemotherapy regimens alter the frequency of CD27
Davern M; Donlon NE; Sheppard AS; Majcher KD; Connell FO; Heeran AB; Grant M; Farrell RA; Hayes C; Bracken-Clarke D; Conroy MJ; Foley E; Toole DO; Bhardwaj A; Ravi N; Reynolds JV; Maher SG; Sullivan JO; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3753-3774. PubMed ID: 35986757
[TBL] [Abstract][Full Text] [Related]
8. PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.
Davern M; Gaughan C; O' Connell F; Moran B; Mylod E; Sheppard AD; Ramjit S; Yun-Tong Kung J; Phelan JJ; Davey MG; Ryan EJ; Butler C; Quinn L; Howard C; Tone E; Phoenix E; Butt WT; Lynam-Lennon N; Maher SG; Ravi N; Donohoe CL; Reynolds JV; Lysaght J; Donlon NE
Front Immunol; 2023; 14():1150754. PubMed ID: 37359545
[TBL] [Abstract][Full Text] [Related]
9. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
[TBL] [Abstract][Full Text] [Related]
11. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
[TBL] [Abstract][Full Text] [Related]
12. Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses.
Mylod E; McKenna E; Davern M; Barr MP; Donlon NE; Bibby BAS; Bhardwaj A; Reynolds JV; Lysaght J; Maher SG; Conroy MJ
Clin Exp Med; 2023 Jun; 23(2):411-425. PubMed ID: 35364779
[TBL] [Abstract][Full Text] [Related]
13. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
[TBL] [Abstract][Full Text] [Related]
14. FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer.
Guan Y; Kraus SG; Quaney MJ; Daniels MA; Mitchem JB; Teixeiro E
Front Oncol; 2020; 10():586. PubMed ID: 32391270
[No Abstract] [Full Text] [Related]
15. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
16. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Luheshi NM; Coates-Ulrichsen J; Harper J; Mullins S; Sulikowski MG; Martin P; Brown L; Lewis A; Davies G; Morrow M; Wilkinson RW
Oncotarget; 2016 Apr; 7(14):18508-20. PubMed ID: 26918344
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition.
Donlon NE; Davern M; Sheppard AD; O'Connell F; Dunne MR; Hayes C; Mylod E; Ramjit S; Temperley H; Mac Lean M; Cotter G; Bhardwaj A; Butler C; Conroy MJ; O'Sullivan J; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
Front Immunol; 2022; 13():823225. PubMed ID: 35154142
[TBL] [Abstract][Full Text] [Related]
18. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
19. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
